Inactive Instrument

Medisun Precision Medicine Ltd.

MPME

MHY595141026

Advanced Medical Equipment & Technology

Medisun Precision Medicine Ltd. announced that it has received $2.25 million in funding

June 21, 2015

On June 22, 2015, Medisun Precision Medicine Ltd. (OTCPK:MPME) closed the transaction.

Latest news about Medisun Precision Medicine Ltd.

Medisun Precision Medicine Ltd. acquired New Sonic Global Limited from Sun Medical Operation Company Limited for $3.8 million.	17-07-24	CI
Accurexa, Inc. Enters into a License Agreement with Medisun Holdings Limited to Use Medisun's NK Cell Technology	17-06-09	CI
Accurexa, Inc. Announces Management Changes	17-04-20	CI
Accurexa, Inc. Appoints Stefan Moll as Chief Financial Officer	17-03-02	CI
Accurexa Inc. Enters into Sublicense Agreement with CNMRGS Inc	17-02-07	CI
Accurexa, Inc. Announces Management Changes	17-01-19	CI
Accurexa Partners with Stemimmune to Develop Stem Cell-Mediated Immunotherapy for Cancer Patients	16-10-18	CI
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer	16-09-07	CI
Medisun Precision Medicine Ltd. Auditor Raises 'Going Concern' Doubt	15-08-05	CI
Accurexa Inc. Announces Directorate Changes	15-07-02	CI
Medisun Precision Medicine Ltd. announced that it has received $2.25 million in funding	15-06-21	CI
Accurexa Inc. announced that it expects to receive $2.25 million in funding.	15-06-15	CI
Accurexa Seeks Financing	15-03-25	CI
Accurexa, Inc. Enters into an Exclusive License Agreement with the Regents of the University of California	14-09-17	CI
Cyto Wave Technologies Inc. will Change its Name to Accurexa Inc	14-08-21	CI
Cyto Wave Technologies Inc. will Change its Ticker to ACXA from CWAV	14-08-21	CI
Cyto Wave Technologies Inc. Appoints Luc H. Meyer as Director	13-09-10	CI
Cyto Wave Technologies Inc. announced that it has received $0.97 million in funding	12-11-28	CI
Cyto Wave Technologies Inc. announced that it expects to receive $1 million in funding.	12-09-14	CI

Chart Medisun Precision Medicine Ltd.

Duration

Period

More charts

Medisun Precision Medicine Ltd. is a development-stage company. The Company is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Company is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+11.91%	227B
DANAHER CORPORATION	+15.46%	197B
INTUITIVE SURGICAL, INC.	+18.58%	141B
BOSTON SCIENTIFIC CORPORATION	+30.36%	110B
SIEMENS HEALTHINEERS AG	+0.65%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+17.74%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.82%	51.75B
AGILENT TECHNOLOGIES, INC.	+11.23%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.73%	37.37B

Other Advanced Medical Equipment & Technology